GlobeNewswire·Nov 10, 2026, 7:00 AM ET

CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CALC

CalciMedica reported cash, cash equivalents, and short-term investments of $13.8 million as of September 30, 2026, with funds expected to cover operations into the second half of 2027.
Data from the Auxora Phase 1b proof-of-concept trial for pulmonary hypertension (PH) is anticipated in mid-2027.
An Investigational New Drug (IND) submission for the oral candidate CM5480 for chronic PH use is also anticipated in mid-2027.
The FDA aligned with CalciMedica's Phase 2b trial design for Auxora in acute pancreatitis (AP), utilizing elevated lactate dehydrogenase (LDH) as a patient enrichment marker.
A one-for-five reverse stock split was completed in August 2026, reducing outstanding shares from approximately 34.5 million to 6.9 million to meet Nasdaq listing requirements.
Research and development expenses totaled $2.3 million for the three months ended September 30, 2026, compared to $3.9 million in the same period of 2025.
General and administrative expenses were $2.4 million for the three months ended September 30, 2026, an increase from $1.8 million in the prior year period.
The company reported a net loss of $1.7 million for the three months ended September 30, 2026, primarily due to a noncash $3.1 million gain from changes in the fair value of financial instruments offsetting operating losses.
Auxora is being evaluated in a planned Phase 1b trial for PH to assess effects on cardiac and pulmonary function, while CM5480 is targeted at right ventricular dysfunction.
The KOURAGE trial for acute kidney injury with respiratory failure remains paused, with no plans to restart the study at this time.

Company: CalciMedica, Inc.
Keywords: Nasdaq:CALC, CalciMedica, Inc.